VICTOZA Drug Patent Profile

When do Victoza patents expire, and what generic alternatives are available?

Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in twenty-seven countries.

The generic ingredient in VICTOZA is liraglutide. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the liraglutide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Victoza

A generic version of VICTOZA was approved as liraglutide by HIKMA on December 23^rd, 2024.

Summary for VICTOZA

International Patents:	63
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	126
Patent Applications:	3,456
Drug Prices:	Drug price information for VICTOZA
Drug Sales Revenues:	Drug sales revenues for VICTOZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VICTOZA
What excipients (inactive ingredients) are in VICTOZA?	VICTOZA excipients list
DailyMed Link:	VICTOZA at DailyMed

See drug prices for VICTOZA

See drug sales revenues for VICTOZA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VICTOZA

NDA:

022341

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VICTOZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Chicago	Early Phase 1
Carmot Therapeutics, Inc.	Phase 1
Yale University	Phase 3

See all VICTOZA clinical trials

Pharmacology for VICTOZA

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Paragraph IV (Patent) Challenges for VICTOZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VICTOZA	Injection	liraglutide	18 mg/3 mL prefilled syringe	022341	1	2016-12-12

US Patents and Regulatory Information for VICTOZA

VICTOZA is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes					Y
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes					Y

Expired US Patents for VICTOZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010

International Patents for VICTOZA

See the table below for patents covering VICTOZA around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	200201997	Dose setting limiter.
Hungary	0202575
Poland	3300721
Russian Federation	2254878	УСТРОЙСТВО ДЛЯ ИНЪЕКЦИЙ С ОГРАНИЧИТЕЛЕМ ДЛЯ УСТАНОВКИ ДОЗ (APPARATUS FOR INJECTIONS WITH DOSE SETTING RESTRICTOR)
South Korea	100556067
World Intellectual Property Organization (WIPO)	2008095762

Supplementary Protection Certificates for VICTOZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2209800	SPC/GB14/079	United Kingdom		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF, AND LIRAGLUTIDE, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF; REGISTERED: CH 65041 20140912; UK EU/1/14/947 20140922
2209800	14C0085	France		PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918
0944648	CA 2009 00041	Denmark
2597103	2017/015	Ireland		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912
2209800	1490067-4	Sweden		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
0944648	SPC/GB09/058	United Kingdom		PRODUCT NAME: LIRAGLUTIDE; REGISTERED: UK EU/1/09/529/001 20090630

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: VICTOZA

Last updated: July 27, 2025

---

Introduction

VICTOZA (liraglutide) is a prescription medication developed by Novo Nordisk, primarily indicated for the management of type 2 diabetes mellitus and, more recently, obesity. As a glucagon-like peptide-1 (GLP-1) receptor agonist, VICTOZA has gained substantial market attention due to its efficacy in glycemic control and weight management. This article analyzes the evolving market dynamics, competitive landscape, regulatory environment, and financial trajectory shaping VICTOZA’s future growth prospects.

---

Market Landscape and Key Drivers

Global Diabetes and Obesity Epidemic

The rise of type 2 diabetes and obesity globally offers a fertile ground for VICTOZA’s expansion. According to the International Diabetes Federation, approximately 537 million adults suffered from diabetes in 2021, with projections exceeding 700 million by 2045. Additionally, obesity prevalence continues to escalate, with over 650 million adults classified as obese worldwide (WHO, 2022). These adverse health trends fuel the demand for effective pharmacotherapy, including GLP-1 receptor agonists like VICTOZA.

Regulatory Approvals and Expanding Indications

Initially approved in 2010 for type 2 diabetes, regulatory agencies such as the FDA and EMA have progressively expanded VICTOZA’s label. Notably, in 2021, the FDA approved Saxenda (liraglutide 3 mg, a higher-dose formulation) for obesity, with VICTOZA’s efficacy informing these decisions. Recent approvals for obesity treatment have significantly broadened the market potential for VICTOZA, positioning it as a dual-purpose therapy.

Competitive Dynamics

The competitive landscape includes other GLP-1 receptor agonists such as Eli Lilly's Trulicity (dulaglutide), AstraZeneca's Ozempic (semaglutide), and Wegovy (semaglutide). Semaglutide-based therapies, especially, have garnered attention due to superior efficacy in weight loss, as demonstrated in multiple clinical trials. However, VICTOZA maintains a competitive edge owing to established safety profile, dose flexibility, and Novo Nordisk’s extensive distribution network.

---

Market Challenges and Opportunities

Pricing and Reimbursement Policies

Pricing strategies and reimbursement agreements significantly influence VICTOZA’s adoption. In key markets like the U.S. and EU, favorable reimbursement schemes enhance access. Conversely, high drug prices pose barriers, particularly in low- and middle-income countries, where affordability limits market penetration.

Patient Adherence and Delivery Format

Injectable administration remains a hurdle for some patients, despite the convenience of once-daily dosing. The advent of more user-friendly delivery devices and potential oral formulations (such as evolving oral GLP-1 formulations under development) could improve adherence and expand VICTOZA’s market share.

Innovations in Formulation and Application

R&D efforts targeting extended-release formulations could mitigate injection frequency, intrinsically boosting market demand. Clinical research demonstrating additional benefits such as cardiovascular risk reduction and renal protection further enhance the drug's value proposition.

---

Financial Trajectory and Revenue Outlook

Current Revenue Performance

In 2022, VICTOZA generated approximately $2.87 billion in global sales for Novo Nordisk, representing sustained growth driven by expanding indications and increasing prevalence of diabetes and obesity worldwide ([2]). Key markets such as the U.S., Europe, and Asia-Pacific remain primary revenue contributors.

Forecasted Growth Patterns

Industry analysts project a compounded annual growth rate (CAGR) of around 10-12% for liraglutide products over the next five years. This upward trajectory is predicated on:

• Market Expansion: Entry into emerging markets with growing disease burdens.
• New Indications: Approval for obesity and potential off-label uses.
• Pipeline Developments: Introduction of fixed-dose combinations and oral formulations.
• Competitive Positioning: Maintaining a premium position through demonstrated clinical benefits.

Potential Revenue Catalysts

1. Expansion into Obesity Care: With Wegovy’s blockbuster success in weight management, VICTOZA is poised to capitalize further by positioning itself as a versatile GLP-1 agonist.
2. Cardiovascular and Renal Benefits: CLARIFY trial data indicating cardiovascular risk reduction can enhance prescriber confidence and widen indications.
3. Strategic Collaborations: Partnerships with payers and healthcare providers to improve access and affordability.

---

Regulatory and Patent Landscapes

Patent Expiry and Generic Competition

Novo Nordisk’s patents protecting VICTOZA’s formulations are anticipated to expire between 2024 and 2028 in key territories. This impending loss of exclusivity could introduce generic competition, exerting downward pressure on prices and margins. However, formulation patents and data exclusivity periods could delay generic entry.

Regulatory Trends

Regulatory authorities are increasingly emphasizing long-term safety and cardiovascular outcomes for diabetes drugs. Ongoing post-marketing studies and real-world evidence will be pivotal in maintaining regulatory approval and market confidence.

---

Conclusion

VICTOZA remains a cornerstone in GLP-1 receptor agonist therapy, with a robust market position driven by escalating global diabetes and obesity rates. Strategic innovation, regulatory advancements, and market expansion efforts underpin its promising financial trajectory. Nevertheless, competitive pressures, patent expiries, and reimbursement challenges necessitate vigilant adaptation to sustain growth. The coming years will be decisive in defining VICTOZA’s long-term role within a patent-competitive and evolving therapeutic landscape.

---

Key Takeaways

• The global rise in type 2 diabetes and obesity drives sustained demand for VICTOZA.
• Expanding indications into obesity and cardiovascular risk reduction significantly enhance revenue prospects.
• Market share will depend on successful navigation of patent expiries and competitive innovations.
• Reimbursement and patient adherence strategies are critical for broader access.
• Investment in formulation improvements and pipeline innovations can secure long-term growth.

---

FAQs

Q1: What distinguishes VICTOZA from its competitors in the GLP-1 market?
A: VICTOZA's long-standing clinical data, established safety profile, flexible dosing, and integrated manufacturing infrastructure provide a competitive edge over newer entrants like semaglutide-based therapies.

Q2: How will upcoming patent expiries affect VICTOZA’s market share?
A: Patent expiries between 2024-2028 may pave the way for generic competition, potentially reducing revenue margins. Novo Nordisk’s strategies include extending patent protections through formulation patents and expanding indications to maintain market leadership.

Q3: What role do regulatory approvals play in VICTOZA’s financial outlook?
A: Regulatory endorsements for new indications, such as obesity and cardiovascular benefits, expand the drug’s therapeutic scope, boosting sales and market penetration.

Q4: Can VICTOZA's financial growth sustain amid increasing competition?
A: Yes, provided it continues to innovate—through new formulations, indications, and clinical data—that reinforce its clinical and commercial value.

Q5: What are the key challenges facing VICTOZA over the next five years?
A: Patent expirations, pricing pressures, payer reimbursement hurdles, and competition from other advanced GLP-1 agents represent significant challenges that require strategic management.

---

References

1. International Diabetes Federation. IDF Diabetes Atlas, 2022.
2. Novo Nordisk. Financial Reports 2022.